Aleniglipron Phase 2 Body Composition Study

Study Summary

This is a randomized, double-blind, placebo-controlled study evaluating the effects of aleniglipron on body composition in participants living with obesity. Participants will be randomized to aleniglipron or placebo in a ratio of 5:1. Participants will receive multiple ascending QD doses of aleniglipron or placebo in titration steps of 4 weeks duration for a total of 40 weeks of treatment.

Conditions

Obesity, Overweight, or Chronic Weight Management

Interventions / Drugs

aleniglipron or placebo

View on ClinicalTrials.gov ↗

Sponsor

GPCR

Structure Therapeutics

GPCR Therapeutics

C60/100

Study Details

Enrollment71 participants

Primary Completion—

Lead SponsorGasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

Data Retrieved2026-04-11 04:14:51.096542+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.